...
Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?
Received Date : 14 Mar 2017
Accepted Date : 05 Apr 2017
Cemil Bilir, M.D. a , Can Sarisozen, PhD b
a Sakarya University School of Medicine, Department of Medical Oncology, Turkey
b Northeastern University, Center for Pharmaceutical Biotechnology and Nanomedicine, USA
Doi: https://doi.org/10.1016/j.jons.2017.04.001 - Article's Language: EN
Journal of Oncological Sciences 3 (2017) 52-56
ABSTRACT
Tryptophan (Trp) is one of the important essential amino acids and Kynurenine pathway (KP) is the first and rate limiting step of degrading Trp to active metabolites. Recent studies showed that KP metabolites have antimicrobial and immunosuppressive roles. The main controller enzyme of this pathway is indoleamine-2,3-dioxygenase (IDO). IDO is an intracellular monomeric, heme-containing enzyme that controls the Trp breakdown in the KP. In this review, we discuss IDO functions on cancer progression and prognosis, and possible therapeutic aspects of inhibition of IDO on cancer immunotherapy.
Keywords: Indoleamine 2,3-dioxygenase; Kynurenine pathway; Cancer
JOURNAL of
EN